Chemomab Therapeutics Ltd - ADR
General ticker "CMMB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $29.5M
Chemomab Therapeutics Ltd - ADR follows the US Stock Market performance with the rate: 45.3%.
Estimated limits based on current volatility of 3.4%: low 1.59$, high 1.70$
Factors to consider:
- Current price 19.5% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.43$, 1.43$]
- 2024-12-30 to 2025-12-30 estimated range: [0.60$, 1.80$]
Financial Metrics affecting the CMMB estimates:
- Negative: Non-GAAP EPS, $ of -2.12 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -79.89 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
- Positive: Interest expense per share, $ of 0 <= 0
- Negative: -1.03 < Inventory ratio change, % of 0
Short-term CMMB quotes
Long-term CMMB plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.48MM | $28.53MM | $25.46MM |
| Operating Income | $-12.48MM | $-28.53MM | $-25.46MM |
| Non-Operating Income | $0.00MM | $0.35MM | $1.24MM |
| Interest Expense | $0.11MM | $0.00MM | $0.00MM |
| R&D Expense | $6.33MM | $16.98MM | $18.38MM |
| Income(Loss) | $-12.48MM | $-28.18MM | $-24.22MM |
| Taxes | $0.00MM | $-0.53MM | $0.00MM |
| Profit(Loss) | $-12.48MM | $-27.65MM | $-24.22MM |
| Stockholders Equity | $61.47MM | $36.22MM | $17.00MM |
| Inventory | $47.50MM | $0.00MM | $0.00MM |
| Assets | $64.35MM | $43.06MM | $22.15MM |
| Operating Cash Flow | $-12.37MM | $-20.37MM | $-23.61MM |
| Capital expenditure | $0.24MM | $0.07MM | $0.00MM |
| Investing Cash Flow | $-45.19MM | $19.53MM | $15.88MM |
| Financing Cash Flow | $61.07MM | $-0.81MM | $3.50MM |
| Earnings Per Share* | $-1.21 | $-2.43 | $-2.06 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.